Shuguang Yang

Shuguang Yang

Auto-generated profile, based on publicly available information

Shuguang Yang

Department of Critical Care Medicine, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, PR China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Medicine
Verified
Journal Article
Open access
SYShuguang Yang
Shuguang Yang
HZHuiying Zhao
Huiying Zhao
HWHuixia Wang
Huixia Wang
HZHua Zhang
Hua Zhang
YAYouzhong An
Youzhong An
Background and aims: To identify the efficacy and safety of remifentanil when compared with other opioids in adult critically ill patients. Methods: We searched for studies in the Cochrane Library, MEDLINE, and EMBASE that had been published up to May 31st, 2019. Randomized clinical trials using remifentanil comparing with other opioids for analgesia were included. Two reviewers independently applied eligibility criteria, assessed quality, and extracted data. Duration of mechanical ventilation was the primary outcome, and secondary outcomes included weaning time, intensive care unit (ICU), length of stay (LOS), hospital LOS, mortality, side effects, and costs. Results: Fifteen studies with 1233 patients were included. Remifentanil was associated with a significant reduction in the duration of mechanical ventilation in the adult ICU patients when compared with other opioids (P = .01). Remifentanil also reduced the weaning time (P = .02) and the ICU LOS when compared with other opioids (P = .01). There was no difference in the hospital LOS (P = .15), side effects (P = .39), and mortality (P = .79) between remifentanil and other opioids, what's more, remifentanil increased the costs of anesthesia (P < .001) but did not increase cost of hospitalization (P = .30) when comparing with other opioids. Conclusions: Remifentanil reduced the duration of mechanical ventilation, weaning time, and ICU LOS when compared with other opioids in adult critically ill patients. Higher quality RCTs are necessary to prove our findings. PROSPERO registration number: CRD42016041438.

16 April 2026 in Clinics
Verified
Journal Article
Open access
YSYao Sun
Yao Sun
SYShuguang Yang
Shuguang Yang
ZXZengli Xiao
Zengli Xiao
YAYouzhong An
Youzhong An
HZHuiying Zhao
Huiying Zhao
This study aims to evaluate the association between SII and the prevalence of MetS in the female population of the United States, utilizing data from the National Health and Nutrition Examination Survey (NHANES) 2013-2018. The study analyzed data from 6140 participants. The association between SII and MetS was investigated using both univariate and multivariable analyses. Additionally, the relationship between SII and all-cause as well as cardiovascular mortality was assessed through Cox proportional hazards regression models. MetS was prevalent in 37.52% of the study population. Participants diagnosed with MetS showed higher SII scores compared to those without MetS. There was a nonlinear "J"-shaped dose-response relationship between increased SII levels and increased all-cause mortality in the MetS population. The same trend of relationship between SII levels and cardiovascular mortality was observed in people aged 60-years and older in the MetS population. The results of this study suggest that there is a significant association between elevated SII and the presence of MetS, and that systemic inflammation indicated by SII may contribute to the development and progression of MetS and its associated complications. Further studies are warranted to elucidate the underlying mechanisms between SII and MetS and to evaluate the clinical utility of SII in risk stratification and management strategies.